MS Cases Double in England Over 20 Years; Life Expectancy Rises
Multiple sclerosis spasticity cannabis treatments are gaining attention as MS cases double in England over 20 years. Improved survival rates mean more patients live longer with chronic symptoms. Cannabis therapies offer promising options for managing…
Investigating Medicinal Cannabis for Muscle Spasticity and Spasms
This muscle spasticity cannabis study evaluates the effectiveness and adverse events of medicinal cannabis in patients with muscle spasticity or spasms. CBD-only products showed meaningful improvements in sleep disturbance, fatigue, and pain interference…
Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
This cannabis MS spasticity review examines nine trials with 2,544 patients but finds critically unreliable pooled estimates due to extreme heterogeneity. The meta-analysis reports numerically implausible effect sizes and suspected publication bias.…
Enhancing Endocannabinoid System for Residual Disease in MS
This clinical study endocannabinoid system approach addresses residual disease in relapse-free multiple sclerosis patients. High-efficacy therapies reduce relapses but symptoms persist. Enhancing the endocannabinoid system offers new treatment insights.